Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
Frida Bugge Askeland, Einar Haukås, Tobias S. Slørdahl, Anja Klostergaard, Tatjana Alexandersen, Liv Osnes, Anna Lysén, Pegah Abdollahi, Lene Kongsgaard Nielsen, Emil Hermansen, Fredrik Schjesvold
Topics & Concepts
MedicineLenalidomideMultiple myelomaBortezomibInternal medicineDexamethasoneMelphalanOncologyClinical endpointAutologous stem-cell transplantationProgressive diseaseMinimal residual diseaseGastroenterologyRegimenSurgeryClinical trialBone marrowChemotherapyMultiple Myeloma Research and TreatmentsCAR-T cell therapy researchChemical Reactions and Isotopes